Hence, further pre-clinical data and clinical trials aiming at translating adenosine signaling inhibition strategies in EGFR-mutated NSCLC are needed to target the dysregulated immunometabolism in the TME, in order to overcome primary resistance to immunotherapy. Here, EGFR is linked to non-small cell lung carcinoma.